Activation of the mGlu7 receptor elicits antidepressant-like effects in mice
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Broad evidence indicates that modulation of the glutamatergic system could be an efficient way to achieve antidepressant activity. Metabotropic glutamate receptor (mGlu receptor) ligands seem to be promising agents to treat several central nervous system disorders, including psychiatric ones.
The aim of our study was to investigate potential antidepressant-like activity of the first, selective, and bio-available mGlu7 receptor agonist, AMN082 (N,N′-dibenzyhydryl-ethane-1,2-diamine dihydrochloride), in wild-type (WT) and mGlu7 receptor knock-out (KO) mice.
Materials and methods
The forced swim test (FST) and the tail suspension test (TST) in mice were used to assess antidepressant-like activity of AMN082.
We found that AMN082, administered IP, induced a dose-dependent decrease in the immobility time of WT animals in the FST and TST, suggesting antidepressant-like potency of an mGlu7 receptor agonist. Moreover, AMN082 did not change the behaviour of mGlu7 receptor KO mice compared to WT littermates in the TST, while imipramine, used as a reference control, significantly reduced their immobility, indicating an mGlu7 receptor-dependent mechanism of the antidepressant-like activity of AMN082. However, at high doses, AMN082 significantly decreased spontaneous locomotor activity of both mGlu7 receptor KO mice and WT control animals, suggesting off-target activity of AMN082 resulting in hypo-locomotion.
These results strongly suggest that activation of the mGlu7 receptor elicits antidepressant-like effects.
- Activation of the mGlu7 receptor elicits antidepressant-like effects in mice
Volume 194, Issue 4 , pp 555-562
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Antidepressant drugs
- Forced swim test
- Locomotor activity
- mGlu7 receptor
- Tail suspension test
- Industry Sectors
- Author Affiliations
- 1. Department of Neurobiology, Institute of Pharmacology Polish Academy of Sciences, Smetna 12, 31-343, Krakow, Poland
- 2. Neuroscience Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
- 3. Department of Drug Management, Collegium Medicum, Jagiellonian University, Krakow, Poland